Hypoglycaemia with Oral Antidiabetic Drugs
Tóm tắt
Background: Hypoglycaemia is an acute complication associated with intensive treatment of patients with diabetes mellitus. This complication poses a major challenge in diabetes management. Furthermore, severe hypoglycaemia may be life threatening. Although hypoglycaemia is more often associated with insulin treatment, oral hypoglycaemic agents have the potential to trigger hypoglycaemia. Aim: The aim of this study was to quantify the incidence of hypoglycaemic events and to describe the pattern of these incident events during the first 9 months of treatment with four oral antidiabetic drugs, rosiglitazone, pioglitazone, nateglinide and repaglinide, prescribed in general practice in England. Methods: We used data collected for prescription-event monitoring (PEM) studies of rosiglitazone, pioglitazone, nateglinide and repaglinide. PEM is an observational, non-interventional, incept cohort study. Observation time for each patient and incidence rate (IR) per 1000 patient-years of treatment for hypoglycaemia was calculated for each drug cohort. Smoothed hazard estimates were plotted over time. Case/non-case analysis was performed to describe and compare patients who had at least one hypoglycaemic event in the first 9 months of treatment with those who did not. Results: The total number of patients included in the analysis was 14373, 12768, 4549 and 5727 in rosiglitazone, pioglitazone, nateglinide and repaglinide cohorts, respectively. From these, 276 patients experienced at least one episode of hypoglycaemia. The IR was between 50% and 100% higher in patients receiving treatment with meglitinides compared with those treated with the thiazolidinediones (TZDs) [IR = 9.94, 9.64, 15.71 and 20.32 per 1000 patient-years for rosiglitazone, pioglitazone, nateglinide and repaglinide, respectively]. The plot of the hazard function and the estimated shape parameter from the Weibull regression model showed that pioglitazone, nateglinide and repaglinide had non-constant (decreasing) hazards over time, whereas the hazard for rosiglitazone-treated patients was approximately constant over time. Nateglinide and repaglinide had similar shape hazard function, indicating a significantly higher number of hypoglycaemic episodes shortly after starting treatment. For women treated with TZDs, hypoglycaemia was reported more frequently than for men. Conclusion: This analysis shows that the frequency of reported hypoglycaemia within the study cohorts was relatively low. The rates of hypoglycaemia were not equal between drug classes. Treatment with nateglinide or repaglinide was characterized by a higher incidence of hypoglycaemia at the beginning of treatment. Further investigation is necessary to assess whether women treated with TZDs are more prone to hypoglycaemia than men. Findings from this study should be taken into account with other clinical and pharmacoepidemiological studies.
Tài liệu tham khảo
WHO Department of Noncommunicable Disease Surveillance. Definition, diagnosis and classification of diabetes mellitus and its complications [online]. Available from URL:
http://www.staff.ncl.ac.uk/philip.home/who_dmc.htm#DefinDiag
[Accessed 2008 Apr 28]
citation_journal_title=Diabetes Care; citation_title=Global prevalence of diabetes: estimates for the year 2000 and projections for 2030; citation_author=S Wild, G Roglic, A Green; citation_volume=27; citation_issue=5; citation_publication_date=2004; citation_pages=1047-53; citation_doi=10.2337/diacare.27.5.1047; citation_id=CR2
citation_journal_title=Diabetes Metab; citation_title=Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives; citation_author=M Virally, JF Blickle, J Girard; citation_volume=33; citation_issue=4; citation_publication_date=2007; citation_pages=231-44; citation_doi=10.1016/j.diabet.2007.07.001; citation_id=CR3
citation_journal_title=Med J Aust; citation_title=Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital; citation_author=Z Hussein, JM Wentworth, AJ Nankervis; citation_volume=181; citation_issue=10; citation_publication_date=2004; citation_pages=536-9; citation_id=CR4
citation_journal_title=JAMA; citation_title=Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group; citation_author=RC Turner, CA Cull, V Frighi; citation_volume=281; citation_issue=21; citation_publication_date=1999; citation_pages=2005-12; citation_doi=10.1001/jama.281.21.2005; citation_id=CR5
citation_journal_title=Diabetes Care; citation_title=Frequency of severe hypoglycemia requiring emergency treatment in type 1 and 417 type 2 diabetes: a population-based study of health service resource use; citation_author=GP Leese, J Wang, J Broomhall; citation_volume=26; citation_issue=4; citation_publication_date=2003; citation_pages=1176-80; citation_doi=10.2337/diacare.26.4.1176; citation_id=CR6
citation_journal_title=Diabetologia; citation_title=Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes; citation_author=PE Cryer; citation_volume=45; citation_issue=7; citation_publication_date=2002; citation_pages=937-48; citation_doi=10.1007/s00125-002-0822-9; citation_id=CR7
citation_journal_title=Clin Diabetes; citation_title=Hypoglycemia: an excuse for poor glycemic control?; citation_author=M Saleh, G Grunberger; citation_volume=19; citation_issue=4; citation_publication_date=2001; citation_pages=161-7; citation_doi=10.2337/diaclin.19.4.161; citation_id=CR8
citation_journal_title=Drug Saf; citation_title=Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England; citation_author=R Kasliwal, L Wilton, SAW Shakir; citation_volume=31; citation_issue=10; citation_publication_date=2008; citation_pages=839-50; citation_doi=10.2165/00002018-200831100-00003; citation_id=CR9
citation_journal_title=Acta Diabetol; citation_title=Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study; citation_author=B Twaites, LV Wilton, D Layton; citation_volume=44; citation_issue=4; citation_publication_date=2007; citation_pages=233-9; citation_doi=10.1007/s00592-007-0010-y; citation_id=CR10
citation_journal_title=Acta Diabetol; citation_title=Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study; citation_author=V Marshall, L Wilton, S Shakir; citation_volume=43; citation_issue=1; citation_publication_date=2006; citation_pages=6-13; citation_doi=10.1007/s00592-006-0203-9; citation_id=CR11
Summary of product characteristics for Avandia (rosiglita-zone maleate), Middlesex: GlaxoSmithKline UK, 2008 Mar [online]. Available from URL:
http://emc.medicines.org.uk/medicine/3200/SPC/Avandia+4mg+%26+8mg+film-coated+Tablets/#UNDESIRABLE_EFFECTS
[Accessed 2009 Apr 15]
Summary of product characteristics for Actos (pioglitazone hydrochloride), Buckinghamshire: Takeda UK Limited, 2007 Sep [online]. Available from URL:
http://emc.medicines.org.uk/medicine/4236/SPC/Actos+Tablets/#UNDESIRABLE_EFFECTS
[Accessed 2009 Apr 15]
citation_journal_title=Diabet Med; citation_title=Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus; citation_author=JJ Nolan, NP Jones, R Patwardhan; citation_volume=17; citation_issue=4; citation_publication_date=2000; citation_pages=287-94; citation_doi=10.1046/j.1464-5491.2000.00269.x; citation_id=CR14
citation_journal_title=Diabetes Care; citation_title=Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group; citation_author=S Aronoff, S Rosenblatt, S Braithwaite; citation_volume=23; citation_issue=11; citation_publication_date=2000; citation_pages=1605-11; citation_doi=10.2337/diacare.23.11.1605; citation_id=CR15
citation_journal_title=Int J Clin Pract; citation_title=Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy; citation_author=J Rosenstock, D Einhorn, K Hershon; citation_volume=56; citation_issue=4; citation_publication_date=2002; citation_pages=251-7; citation_id=CR16
citation_journal_title=Diabet Med; citation_title=Effect of met-formin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled type 2 diabetes; citation_author=MW Stewart, DT Cirkel, K Furuseth; citation_volume=23; citation_issue=10; citation_publication_date=2006; citation_pages=1069-78; citation_doi=10.1111/j.1464-5491.2006.01942.x; citation_id=CR17
citation_journal_title=Diabet Med; citation_title=Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients; citation_author=BH Wolffenbuttel, R Gomis, S Squatrito; citation_volume=17; citation_issue=1; citation_publication_date=2000; citation_pages=40-7; citation_doi=10.1046/j.1464-5491.2000.00224.x; citation_id=CR18
citation_journal_title=JAMA; citation_title=Oral antihyperglycemic therapy for type 2 diabetes: scientific review; citation_author=SE Inzucchi; citation_volume=287; citation_issue=3; citation_publication_date=2002; citation_pages=360-72; citation_doi=10.1001/jama.287.3.360; citation_id=CR19
citation_journal_title=Diabetes Care; citation_title=Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes; citation_author=RG Moses, R Gomis, KB Frandsen; citation_volume=24; citation_issue=1; citation_publication_date=2001; citation_pages=11-5; citation_doi=10.2337/diacare.24.1.11; citation_id=CR20
citation_journal_title=J Clin Endocrinol Metab; citation_title=Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia; citation_author=C Saloranta, K Hershon, M Ball; citation_volume=87; citation_issue=9; citation_publication_date=2002; citation_pages=4171-6; citation_doi=10.1210/jc.2002-020068; citation_id=CR21
citation_title=PEM in the UK; citation_inbook_title=Pharmacovigilance; citation_publication_date=2007; citation_pages=307-16; citation_id=CR22; citation_author=SAW Shakir; citation_publisher=John Wiley & Sons Ltd
citation_journal_title=Diabetes Care; citation_title=A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes; citation_author=M John Sutton, M Rendell, P Dandona; citation_volume=25; citation_issue=11; citation_publication_date=2002; citation_pages=2058-64; citation_doi=10.2337/diacare.25.11.2058; citation_id=CR23
citation_journal_title=Clin Ther; citation_title=Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multi-center, randomized, double-blind, parallel-group trial; citation_author=M Tan, D Johns, GG Gonzalez; citation_volume=26; citation_issue=5; citation_publication_date=2004; citation_pages=680-93; citation_doi=10.1016/S0149-2918(04)90068-9; citation_id=CR24
citation_journal_title=N Engl J Med; citation_title=Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy; citation_author=SE Kahn, SM Haffner, MA Heise; citation_volume=355; citation_issue=23; citation_publication_date=2006; citation_pages=2427-43; citation_doi=10.1056/NEJMoa066224; citation_id=CR25
citation_journal_title=Diabetes Obes Metab; citation_title=Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial; citation_author=G Derosa, AV Gaddi, MN Piccinni; citation_volume=8; citation_issue=2; citation_publication_date=2006; citation_pages=197-205; citation_doi=10.1111/j.1463-1326.2005.00480.x; citation_id=CR26
citation_journal_title=Am J Med; citation_title=Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study; citation_author=MS Kipnes, A Krosnick, MS Rendell; citation_volume=111; citation_issue=1; citation_publication_date=2001; citation_pages=10-7; citation_doi=10.1016/S0002-9343(01)00713-6; citation_id=CR27
citation_journal_title=Curr Med Res Opin; citation_title=An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes; citation_author=V Vongthavaravat, BL Wajchenberg, JN Waitman; citation_volume=18; citation_issue=8; citation_publication_date=2002; citation_pages=456-61; citation_doi=10.1185/030079902125001236; citation_id=CR28
citation_journal_title=Clin Ther; citation_title=Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multi-center, parallel-group study; citation_author=V Mattoo, D Eckland, M Widel; citation_volume=27; citation_issue=5; citation_publication_date=2005; citation_pages=554-67; citation_doi=10.1016/j.clinthera.2005.05.005; citation_id=CR29
citation_journal_title=Diabetes Res Clin Pract; citation_title=Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone; citation_author=L Jovanovic, DR Hassman, B Gooch; citation_volume=63; citation_issue=2; citation_publication_date=2004; citation_pages=127-34; citation_doi=10.1016/j.diabres.2003.09.004; citation_id=CR30
citation_journal_title=Diabet Med; citation_title=Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone; citation_author=P Raskin, J McGill, MF Saad; citation_volume=21; citation_issue=4; citation_publication_date=2004; citation_pages=329-35; citation_doi=10.1111/j.1464-5491.2004.01143.x; citation_id=CR31
citation_journal_title=Diabetes Care; citation_title=Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin; citation_author=P Raskin, L Klaff, J McGill; citation_volume=26; citation_issue=7; citation_publication_date=2003; citation_pages=2063-8; citation_doi=10.2337/diacare.26.7.2063; citation_id=CR32
citation_journal_title=Diabetes Care; citation_title=Repaglinide versus nateglinide monotherapy: a randomized, multi-center study; citation_author=J Rosenstock, DR Hassman, RD Madder; citation_volume=27; citation_issue=6; citation_publication_date=2004; citation_pages=1265-70; citation_doi=10.2337/diacare.27.6.1265; citation_id=CR33
citation_journal_title=Diabetes Care; citation_title=Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo; citation_author=JB Kalbag, YH Walter, JR Nedelman; citation_volume=24; citation_issue=1; citation_publication_date=2001; citation_pages=73-7; citation_doi=10.2337/diacare.24.1.73; citation_id=CR34
citation_journal_title=J Clin Pharmacol; citation_title=Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study; citation_author=L Jovanovic, G Dailey, WC Huang; citation_volume=40; citation_issue=1; citation_publication_date=2000; citation_pages=49-57; citation_doi=10.1177/00912700022008694; citation_id=CR35
citation_journal_title=Diabetes Care; citation_title=Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes; citation_author=J Rosenstock, SG Shen, MR Gatlin; citation_volume=25; citation_issue=9; citation_publication_date=2002; citation_pages=1529-33; citation_doi=10.2337/diacare.25.9.1529; citation_id=CR36
citation_journal_title=Diabetes Obes Metab; citation_title=Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study; citation_author=J Patel, RJ Anderson, EB Rappaport; citation_volume=1; citation_issue=3; citation_publication_date=1999; citation_pages=165-72; citation_doi=10.1046/j.1463-1326.1999.00020.x; citation_id=CR37
citation_journal_title=Diabetes Metab; citation_title=Therapeutic compliance: a prospective analysis of various factors involved in the adherence rate in type 2 diabetes; citation_author=Y Bezie, M Molina, N Hernandez; citation_volume=32; citation_issue=6; citation_publication_date=2006; citation_pages=611-6; citation_doi=10.1016/S1262-3636(07)70316-6; citation_id=CR38
citation_journal_title=Am J Manag Care; citation_title=Oral antidiabetic medication adherence and glycemic control in managed care; citation_author=Y Rozenfeld, JS Hunt, C Plauschinat; citation_volume=14; citation_issue=2; citation_publication_date=2008; citation_pages=71-5; citation_id=CR39